Skip to main content
. 2019 Jun 28;30(9):1472–1478. doi: 10.1093/annonc/mdz200

Figure 2.

Figure 2.

(A) Kaplan–Meier estimates of recurrence-free survival (RFS) for all assessable patients undergoing curative intent surgery for early pancreatic cancer, stratified by pre-operative ctDNA status: detectable (positive) versus undetectable (negative). (B) Kaplan–Meier estimate for overall survival (OS) for matched patients, stratified by pre-operative ctDNA status. (C) Kaplan–Meier estimates for RFS, stratified by postoperative ctDNA status. (D) Kaplan–Meier estimates for OS, stratified by post-operative ctDNA status. (E, F) Kaplan–Meier estimates for RFS (E) and OS (F) for patients’ whose ctDNA status changes from detectable (positive) pre-operatively to undetectable (negative) post-operatively compared with patients whose ctDNA status remains undetectable (negative) both pre- and post-operatively.